|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1360 - 0.2260|
|52 Week Range||0.0900 - 0.4960|
|Beta (3Y Monthly)||5.69|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
REDWOOD CITY, Calif., Aug. 05, 2019 -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 Canaccord Genuity.
Rezolute, Inc. (“Rezolute”) (RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative therapies targeting metabolic and orphan diseases, announced today that Handok, Inc. (“Handok”) and Genexine, Inc. (“Genexine”), exercised their combined full $20 million option to purchase shares of Rezolute common stock, increasing their combined aggregate investment in Rezolute to $45 million. Each share of common stock was priced at $0.29 in this offering. “We are very appreciative of the continued support of Genexine and Handok.
NEW YORK , April 18, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
Rezolute, Inc. (“Rezolute” or “Company”) (RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, announced today that it has entered into a $25 million preferred stock purchase agreement with two pharmaceutical companies that have elected to make a strategic investment in the Company.